Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Mizuho

The Analyst Says 'Impressive Phase 3 Data Highlight Best-In-Class Opportunity' For Concert Pharma

Concert Pharmaceuticals Inc (NASDAQ:CNCE) has released highly positive Phase 3 data for their alopecia areata drug CTP-543 from the THRIVE-AA1 trial. Mizuho says that the efficacy supports its view that CTP-543 potentially has best-in-class efficacy amongst the three main oral JAK inhibitors in late-stage development for alopecia areata (CTP-543, Eli Lilly And Co's (NYSE: LLY)…

Benzinga

Check Out What Whales Are Doing With COIN

Someone with a lot of money to spend has taken a bearish stance on Coinbase Global (NASDAQ:COIN). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Mizuho Remains Bullish On JD Post Q1 - Read Why

Mizuho analyst James Lee maintained a Buy on JD.com, Inc (NASDAQ:JD) with a price target of $90 (75% upside). JD beat top line and margins due to its competitive advantage in supply chain and logistics, which enabled the company to gain share. The COVID lockdown impact in 2Q22 was more than Lee's expectation at 5% YoY growth,…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Coinbase Global Whale Trades For May 18

Benzinga

Ahead Of Upcoming Data On Three Programs, Analysts Remain On Sidelines For Wave Life Sciences

RBC Capital writes that Wave Life Sciences Ltd's (NASDAQ: WVE) Q1 earnings are largely incremental.

Benzinga

Mizuho Sees Relief For This Small-Cap Stock After Patent Legal Overhang Lifted

The US Patent Trial and Appeal Board (PTAB) issued a final written decision in favor of Concert Pharmaceuticals Inc (NASDAQ:CNCE) regarding the post-grant review (PGR) for the '659 method-of-use patent. The '659 patent claims methods of treating hair loss, including alopecia areata with certain doses of CTP-543, a deuterated form of ruxolitinib, JAK 1/2…

Benzinga

Mizuho Remains Bullish On This Small-Cap Stock's Migraine Candidate, But Why Did It Cut Price Target

Mizuho Securities says that the Satsuma Pharmaceuticals Inc (NASDAQ: STSA) story is essentially unchanged. It remains bullish on STS101's potential as an effective, safe, and reliable intranasal dihydroergotamine (DHE) for migraine.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Jack Dorsey's Block Would Shine If It Wasn't For Bitcoin Holding It Back, Says Analyst

Equity research analysts from Mizuho believe that Jack Dorsey’s payments firm Block Inc (NASDAQ: SQ) should downplay its association with Bitcoin (CRYPTO:

Benzinga

Why These Beyond Meat Analysts Are Barbecuing Price Targets After $100M Q1 Loss: 'Lower Likelihood Of Disruption'

Beyond Meat Inc (NASDAQ: BYND) shares traded higher Thursday before moving lower in the afternoon, and remain down 56.6% year-to-date after the company reported a larger-than-expected first-quarter net lo

Benzinga

Coinbase Global Whale Trades For May 06

A whale with a lot of money to spend has taken a noticeably bearish stance on Coinbase Global. Looking at options history for Coinbase Global (NASDAQ:COIN) we detected 44 strange trades.

Benzinga

Mizuho Maintains Buy Rating for Avalara: Here's What You Need To Know

Mizuho has decided to maintain its Buy rating of Avalara (NYSE:AVLR) and lower its price target from $160.00 to $110.00. Shares of Avalara are trading up 8.77% over the last 24 hours, at $76.12 per share. A move to $110.00 would account for a 44.51% increase from the current share…

Benzinga

Mizuho Maintains Buy Rating for Enterprise Prods Partners: Here's What You Need To Know

Mizuho has decided to maintain its Buy rating of Enterprise Prods Partners (NYSE:EPD) and raise its price target from $30.00 to $32.00. Shares of Enterprise Prods Partners are trading up 2.28% over the last 24 hours, at $26.20 per share.

Benzinga

Mizuho Continues To See Upside In Alibaba, JD, Baidu, Dada Amid Odds

Mizuho saw a challenging 1H22 for China's internet, given the ongoing disruptions to consumer spending and business activities from COVID restrictions. Mizuho expects the negative impact to spread across all internet segments, including e-commerce, advertising, and cloud computing.

Benzinga

Looking At Coinbase Global's Recent Whale Trades

A whale with a lot of money to spend has taken a noticeably bullish stance on Coinbase Global. Looking at options history for Coinbase Global (NASDAQ:COIN) we detected 21 strange trades.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Here's Why Analysts Remained Bullish On Western Digital Post Q3

Analysts reiterated their ratings on Western Digital Corporation's (NASDAQ: WDC)

Benzinga

Mizuho Maintains Buy Rating for Atmos Energy: Here's What You Need To Know

Mizuho has decided to maintain its Buy rating of Atmos Energy (NYSE:ATO) and raise its price target from $119.00 to $131.00. Shares of Atmos Energy are trading down 1.67% over the last 24 hours, at $114.86 per share. A move to $131.00 would account for a 14.05% increase from the…

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 29, 2022

Upgrades

Benzinga

Mizuho Maintains Neutral Rating for Texas Instruments: Here's What You Need To Know

Mizuho has decided to maintain its Neutral rating of Texas Instruments (NASDAQ:TXN) and lower its price target from $190.00 to $175.00. Shares of Texas Instruments are trading up 0.66% over the last 24 hours, at $169.56 per share.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Looking At Coinbase Global's Recent Whale Trades

Benzinga

Analysts Say Acadia's Negative Pain Data Increases Focus On Pimavanserin For Alzheimer's-Related Psychosis

Acadia Pharmaceuticals Inc (NASDAQ:ACAD) announced the primary endpoint miss of the phase 2 POC study of ACP-044 in acute postoperative pain following bunionectomy, a surgical procedure that moves toes back into the correct position. RBC Capital Markets writes that although trends of pain reduction were observed in the 400 mg QID ACP-044 arm compared…

Benzinga

Mizuho Slashes Qualcomm Price Target - Read Why

Mizuho analyst Vijay Rakesh lowered the price target on Qualcomm Inc (NASDAQ:QCOM) to $185 from $210 (35.1% upside) and kept a Buy rating. The first half of 2022 brings "multiple headwinds" to China handset manufacturers from weaker 5G demand, extended COVID lockdowns, and a more competitive Apple Inc (NASDAQ:AAPL) iPhone. The headwinds are driving potentially increased radio…

Benzinga

This Is What Whales Are Betting On Block

A whale with a lot of money to spend has taken a noticeably bearish stance on Block. Looking at options history for Block (NYSE:SQ) we detected 21 strange trades.

Benzinga

What Are Whales Doing With Block

A whale with a lot of money to spend has taken a noticeably bearish stance on Block. Looking at options history for Block (NYSE:SQ) we detected 17 strange trades.

Benzinga

Here's Why Mizuho Views Uber As Top Pick

Mizuho analyst James Lee kept a Buy rating on Uber Technologies Inc (NYSE:UBER) with a $72 price target (100% upside). Lee reiterated Uber as a top pick in the U.S. Washington passed a new law that enabled gig drivers to remain as contractors while receiving benefits like injury protection and paid medical leave. The law…

Benzinga

Block Whale Trades For March 31

A whale with a lot of money to spend has taken a noticeably bearish stance on Block. Looking at options history for Block (NYSE:SQ) we detected 53 strange trades.

1 … 7 8 9 10

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.